An injectable gel rebuilt stroke-damaged brain tissue and brought movement back in mice

A stroke caused by a blocked blood vessel leaves behind a cavity of dead tissue that the brain has historically had almost no ability to rebuild on its own. Biomedical engineers at Duke University have developed an injectable material that changes that outcome in mice, transforming the empty cavity into a scaffold that supports new blood vessels, nerve regrowth and measurable recovery of movement. The material works by recruiting the body’s own immune cells into the repair process instead of relying on an external drug to do the healing directly.

What the injectable scaffold is made of

The material is built from what researchers call a microporous annealed particle scaffold, a structure made of individual hydrogel microparticles that link together after injection to form a sponge-like, porous framework inside the stroke cavity. That porous structure gives cells room to move in and begin rebuilding tissue, rather than leaving them to face a dense, uniform gel that would be harder to grow through. Because the material can be injected rather than surgically implanted, it can be delivered directly into the irregular, hard-to-reach cavity a stroke leaves behind.

The work, led by Tatiana Segura, a professor of biomedical engineering at Duke, appeared in the journal Cell Biomaterials, according to a summary of the findings from ScienceDaily. The stroke type modeled in the study is caused by a blood clot rather than a bleed, the more common form of stroke and the one for which existing acute treatments focus almost entirely on removing or dissolving the clot as quickly as possible.

Recruiting the immune system instead of fighting it

Rather than trying to suppress the immune response that follows a stroke, the Duke team engineered the scaffold to work with it. The researchers attached extracellular vesicles, small signaling packages derived from astrocytes, a type of support cell in the brain, directly onto the hydrogel particles, localizing biological signals inside the scaffold so that incoming immune cells encounter them steadily over an extended period rather than in a single burst. That design let the material influence neutrophils, immune cells typically associated with causing additional damage after a stroke, in ways that appeared to shift some of their activity toward a more constructive, repair-supporting role instead.

Neutrophils are usually among the first immune cells to arrive at any injury site, including the brain after a stroke, and they are conventionally viewed as contributing to secondary tissue damage during that early response. Getting the same cells to instead support tissue rebuilding, rather than simply blocking them from reaching the injury, is a different strategy from most anti-inflammatory approaches that have been tested for stroke recovery in the past.

Turning a dead cavity into a rebuilding site

In treated mice, the scaffold helped the stroke cavity grow new blood vessels, a process known as angiogenesis that is essential for delivering oxygen and nutrients to any tissue attempting to regenerate. It also supported the kind of nerve remodeling needed for surviving neurons near the injury site to extend new connections into the repair zone. Turning a cavity that would otherwise remain an empty, scarred void into an environment that actively supports this kind of rebuilding is the central goal of the approach, and it marks a departure from stroke treatments that focus mainly on limiting damage in the earliest hours after a clot forms.

Without intervention, the tissue lost to a stroke is typically replaced by a dense scar and a fluid-filled cavity that provides little structural support for new blood vessels or nerve fibers to grow through. The porous scaffold gives cells a physical framework to build on inside that cavity, addressing a structural barrier to repair that exists even when the surrounding brain tissue still contains cells capable of some regrowth.

Motor recovery observed in mouse models

Mice treated with the injectable scaffold showed improved motor performance compared with untreated animals, a result the researchers link to the combination of new blood vessel growth and nerve remodeling the material encouraged. Motor recovery is one of the most closely watched outcomes in stroke research generally, since loss of movement and coordination is among the most common and disabling long-term consequences of a stroke in people. According to Duke’s Pratt School of Engineering, the scaffold’s ability to improve functional movement, not just tissue appearance under a microscope, is what distinguishes this result from earlier biomaterial approaches that improved local tissue structure without necessarily restoring function.

The road from mice to people

The results so far come entirely from mouse studies, and translating an injectable scaffold like this into a treatment for human stroke patients would require substantial additional testing, including work in larger animal models and eventually controlled human trials to establish safety and effectiveness. Human stroke cavities also vary far more in size and location than the injuries modeled in a laboratory setting, which adds complexity that mouse studies alone cannot fully capture. Even so, the approach represents a meaningfully different strategy from most current stroke treatments, which concentrate almost entirely on the emergency window immediately after a clot forms rather than on rebuilding tissue that has already been lost.

Biomaterial scaffolds of this general type have already been tested in early human trials for other applications, such as wound healing and bone repair, which gives researchers some existing safety framework to build on as they consider how a stroke-specific version might eventually move toward people. Even so, the brain’s sensitivity and the difficulty of accessing a stroke cavity without additional surgical risk mean any human testing pathway would likely take considerably longer than for scaffolds used elsewhere in the body.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview